• Molecular NameNisoldipine
  • SynonymNisoldipin; Nisoldipino [INN-Spanish]; Nisoldipinum [INN-Latin]
  • Weight388.42
  • Drugbank_IDDB00401
  • ACS_NO63675-72-9
  • Show 3D model
  • LogP (experiment)4.53
  • LogP (predicted, AB/LogP v2.0)4.36
  • pkaN/A
  • LogD (pH=7, predicted)4.36
  • Solubility (experiment)0.0199 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-5.0
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds8
  • TPSA113.46
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA calcium channel blocker of the dihydropyridine class.
  • Absorption_value90.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability5.0
  • Protein binding99.0
  • Volume of distribution (VD)2.7 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNisoldipine undergoes dehydrogenation of the dihydropyridine ring to the pyridine nucleus, hydroxylation of the isobutyl ester is the second major biotransformation pathway, with 70 to 80% of urinary metabolites undergoing side chain hydroxylation
  • Half life2 h (beta phase) and 10 to 12 h (gamma phase). Terminal elimination half-life is 7 to 12 h.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A